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Abstract
Cancer cells eventually acquire drug resistance largely via the aberrant expression of ATP-binding cassette (ABC)
transporters, ATP-dependent efflux pumps. Because cancer cells produce ATP mostly through glycolysis, in the present
study we explored the effects of inhibiting glycolysis on the ABC transporter function and drug sensitivity of malignant cells.
Inhibition of glycolysis by 3-bromopyruvate (3BrPA) suppressed ATP production in malignant cells, and restored the
retention of daunorubicin or mitoxantrone in ABC transporter-expressing, RPMI8226 (ABCG2), KG-1 (ABCB1) and HepG2 cells
(ABCB1 and ABCG2). Interestingly, although side population (SP) cells isolated from RPMI8226 cells exhibited higher levels of
glycolysis with an increased expression of genes involved in the glycolytic pathway, 3BrPA abolished Hoechst 33342
exclusion in SP cells. 3BrPA also disrupted clonogenic capacity in malignant cell lines including RPMI8226, KG-1, and HepG2.
Furthermore, 3BrPA restored cytotoxic effects of daunorubicin and doxorubicin on KG-1 and RPMI8226 cells, and markedly
suppressed subcutaneous tumor growth in combination with doxorubicin in RPMI8226-implanted mice. These results
collectively suggest that the inhibition of glycolysis is able to overcome drug resistance in ABC transporter-expressing
malignant cells through the inactivation of ABC transporters and impairment of SP cells with enhanced glycolysis as well as
clonogenic cells.
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Introduction
The emergence of drug-resistant clones during the course of
treatment and the presence of cancer stem cells or cancer-initiating
cells are among the predominant causes of drug resistance in cancer
patients [1,2]. Such drug-resistant cells increase their expression of
ATP-binding cassette (ABC) transporters including P-glycoprotein
(ABCB1), breast cancer resistance protein (BCRP; ABCG2) and
multidrug-resistance-associated protein-1 (MRP-1), which function
as efflux transporters dependent on energy from the hydrolysis of
ATP for a variety of chemotherapeutic drugs [1,2,3,4,5]. Cancer
stem cells or cancer-initiating cells have a tumor-initiating capacity
and appear to be involved in resistance to chemotherapy and tumor
relapse [1,2]. They are considered to be contained in a ‘‘side
population’’ with negative staining of Hoechst 33342 fluorescence
dye, a substrate for BCRP, suggesting higher ABC transporter
activity in these cells [6,7,8,9].
Malignantcellsincreasetheirexpressionofglycolyticenzymesand
glucoseuptaketomarkedlyenhanceglycolysis(aerobicglycolysis;the
Warburg effect), which leads to the production of a large amount of
ATP and biomass such as nucleic acids and lipids essential for cell
survival and division [10,11,12]. Thus, increased aerobic glycolysis is
regarded as a hallmark of cancers and applied to the detection of
malignant lesions in [
18F]fluorodeoxyglucose-positron emission
tomography (FDG-PET) which is widely used in clinics [12,13]. In
parallel with enhanced glycolysis, ATP production by oxidative
phospohorylation in the tricarboxylic acid (TCA) cycle in mito-
chondria is suppressed through oncogenic alterations including the
mutation of p53 [10,12,14]. In sharp contrast to malignant cells with
glycolysis-dependent ATP production, normal cells utilize the TCA
cycle in mitochondria for their ATP [10,11,12,14,15]. These
observations suggest that the inhibition of glycolysis can abolish
ATP production as well as biomass synthesis in cancer cells while
sparing ATP production and cell metabolism in normal quiescent
cells; and thus enhanced glycolysis may become a novel cancer-
specific target for anti-cancer treatment.
Drug resistance has emerged as an important clinical issue in
the treatment of cancers; and ABC transporters are regarded as a
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transporter activity is dependent on ATP [5,16] and because
ATP production in cancer cells is largely dependent on enhanced
glycolysis [10,11,12,14,15], we hypothesized that inhibition of
glycolysis can induce a cancer-specific inactivation of ABC
transporter activity to restore susceptibility to anti-cancer drugs.
We demonstrate herein that inhibition of glycolysis preferentially
targets malignant cells to suppress ATP production, and that
inhibition of glycolysis inactivates ABC transporter activity to
retain anti-cancer agents intracellularly and restore their cytotoxic
effects on malignant cells.
Materials and Methods
Ethics Statement
All procedures involving human specimens were performed
with written informed consent according to the Declaration of
Helsinki and using a protocol approved by the Institutional
Review Board for human protection in University of Tokushima
(Permit number: 240). The mouse experiment was carried out in
strict accordance with the recommendations in the Guide for the
Care and Use of Laboratory Animals of the National Institutes of
Health. The protocol was approved by the Animal Experimen-
tation Committee of the University of Tokushima (Permit number:
10120). All efforts were made to minimize suffering.
Reagents
The following reagents were purchased as indicated: 3BrPA and
verapamil from Sigma (St. Louis, MO); mouse monoclonal anti-
human BCRP from Millipore (Temecula, CA); mouse monoclonal
anti-human MRP1 from Santa Cruz Biotechnology (Santa Cruz,
CA); FITC-rabbit anti-mouse IgG from Zymed Laboratories (San
Francisco, CA); and PE-mouse anti-P-glycoprotein antibody, PE-
mouse anti-human CD138 antibody, and PE-mouse IgG from BD
Bioscience (San Jose, CA).
Cells and cultures
The human KG1 leukemic cell line, RPMI8226 myeloma
(MM) cell line, HepG2 hepatoma cell line, DU145 prostate
carcinoma cell line, and MDA-MB231 breast cancer cell lines
were obtained from American Type Culture Collection (ATCC)
(Rockville, MD). The MM cell line INA6 was kindly provided by
Dr. Renate Burger (University of Kiel, Kiel, Germany). Bone
marrow mononuclear cells (BMMCs) were isolated from fresh
bone marrow aspirates of patients with myeloma and primary
CD138
+ myeloma cells were further sorted using CD138
MicroBeads (Miltenyi Biotec, Bergisch Gladbach, Germany) as
described previously [17,18]. Peripheral blood mononuclear cells
(PBMCs) were isolated from fresh peripheral blood from healthy
donors [18]. KG1 and RPMI8226 cells and primary hematopoi-
etic cells were cultured in RPMI1640 medium (Sigma) supple-
mented with 10% fetal bovine serum (FBS), 100 U/ml of penicillin
G, and 100 mg/ml of streptomycin (Sigma). INA-6 cells were
cultured in RPMI1640 medium supplemented with 10% FBS, 100
U/ml of penicillin G, 100 mg/ml of streptomycin, and 1 ng/ml of
rhIL-6 (PEPROTECH EC, London, UK). HepG2, DU145, and
MDA-MB231 cells were cultured in aMEM (Sigma) supplement-
ed with 10% FBS, 2 mM L-glutamine (Sigma), 100 U/ml of
penicillin G, and 100 mg/ml of streptomycin.
Colony formation assays
Cells were cultured in duplicate at 200–500 cells/ml in 35 mm
dishes containing IMDM (Sigma) with 1.17% of methylcellurose
(R&D Systems), 30% of FBS, 100 U/ml of penicillin G, and
100 mg/ml of streptomycin. After culturing for about 2 weeks,
colonies were visualized and counted under an Olympus BX50
microscope equipped with an UMPlanFI 40X/0.75 objective lens
(Olympus, Tokyo, Japan). Images were recorded with an Olympus
SC35 CCD camera and Viewfinder Lite Software (Pixera, Los
Gatos, CA).
Cell viability assays
Cells were plated out in triplicate in 96-well culture plate and
incubated with drugs. The number of viable cells was determined
by the Cell Counting Kit-8 assay (DOJINDO, Kumamoto, Japan)
according to the manufacturer’s instructions. The absorbance of
each well was measured at 450 nm with a microplate reader
(Model 450 micro plate reader; Bio-Rad Laboratories, Hercules,
CA). Data was shown as the mean+- SD.
Intracellular ATP measurements
Cells were plated in duplicate in 96-well culture plates. Cellular
ATP levels were determined using the CellTiter-Glo luminescent
Cell Viability Assay (Promega, Madison, USA) according to the
manufacturer’s instructions. Luminescent levels were measured by
microplate reader Thermo (Thermo Fisher Varioskan Flash,
Waltham MA).
Flow cytometry
Cells were collected and stained with PE-labeled mouse
monoclonal anti-P-glycoprotein antibody, or with mouse mono-
clonal anti-BCRP or anti-MRP1 antibody followed by FITC-
labeled rabbit anti-mouse IgG antibody as described before [19].
The expression of P-glycoprotein, BCRP, and MRP1 was
determined using Coulter Epics XL-MCL (Beckman & Coulter)
and analyzed by CellQuest software (BD Bioscience). For analysis
of the CD138
+ population, BMMCs were stained with FITC-
labeled mouse anti-CD138 antibody and the population of
CD138
+ myeloma cells was analyzed by flow cytometry. Apoptosis
was evaluated by staining cells with an annexin V-FITC and
propidium iodide (PI) labeling kit (MEBCYTO Apoptosis Kit;
MBL,Nagano, Japan) according to the manufacturer’s instruc-
tions.
Drug accumulation and efflux assay
Cells were cultured in the presence or absence of 3BrPA, and
30 minutes later, 30–100 ng/ml of daunorubicin or 100 ng/ml of
mitoxantrone was added. After incubating for 30 minutes, cells
were washed, and intracellular fluorescence levels were analyzed
by flow cytometry (accumulation phase, AP). For determining
drug efflux levels, the cells were further incubated in the presence
or absence of 3BrPA for 120 minutes, and intracellular fluores-
cence levels were analyzed (efflux phase, EP). Intracellular drug
concentrations at AP and EP were represented as DMFIAP (the
difference of MFI between AP and background) and DMFIEP (the
difference of MFI between EP and background), respectively.
Lactate measurements
After filtering culture media to remove protein, lactate levels
were measured using Lactate Assay Kit (BioVision, Mountain
View, CA). The absorbance of each well was measured at 570 nm
with a microplate reader (Model 450 micro plate reader).
Side population (SP) analysis
Cells were incubated with 5 mg/ml of Hoechst 33342 (Invitro-
gen) for 90 min at 37 uC in the presence or absence of 100 mMo f
verapamil or 3BrPA. After being washed, the cells were
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detect dead cells. Hoechst 33342 was excited with a UV laser at
350 nm, and the SP and main population (MP) cell fractions were
analyzed by flow cytometry (EPICS ALTRA HyperSort, Beckman
& Coulter) with 450 nm (Hoechst blue) and 675 nm (Hoechst red)
filters. The SP and MP fractions were sorted by flow cytometry.
Quantitative real-time PCR
Cells were harvested and total RNA was extracted from cells
using TRIZOL reagent (Invitrogen Life Technologies, Carlsbad,
CA). Equal amounts of total RNA were subjected to reverse
transcription using Superscript II (Invitrogen). Real-time PCR was
performed using Platinum SYBR Green qPCR SuperMix UDG
with Rox (invitrogen) with the following amplification program:
one cycle of 50 uC for 2 minutes and 95 uC for 2 minutes and 40
cycle of 95 uC for 15 seconds and 60 uC for 30 seconds. The
reaction was followed by a melting curve protocol according to the
specifications of the ABI 7300 (Applied Biosystems, Foster City,
CA). Primers used were as follows: hHKII sense 59-TGGAGG-
GACCAACTTCCGTGTGCT-39 and antisense 59-TCAAACA-
GCTGGGTGCCACTGC-39,h GAPDH sense 59-AATCCCAT-
CACCATCTTCCA-39 and antisense 59-TGGACTCCACGAC-
GTACTCA-39,h PDK1 sense 59-CGGATCAGAAACCGACAC-
A-39 and antisense 59-GGATCAGAAACCGACACA-39,h PKM2
sense 59-TCAAGTGCTGCAGTGGGGCCAT-39 and antisense
59-TCACAGCAATGATGGGGGCACGT-39,h PFK2 sense 59-
TGTCGCTTATGGCTGCCGTGT-39 and antisense 59-AGCG-
GGGTGACACTATTGCGT-39, and hHPRT1 (used as a house-
keeping gene for normalization) sense 59-TTTGCTTTCCTT-
GGTCAGGC-39 and antisense 59-GCTTGCGACCTTGACC-
ATCT-39.
Immunoblotting
Cells were harvested and fractioned into cytosolic and
membrane fractions using a Mem-PER Eukaryotic Membrane
Protein Extraction Kit (Thermo Scientific, Rockford, IL).
Membrane fractions were subjected to Immunoblotting analysis
as described previously [18]. Apoptosis inducing factor (AIF) was
used as a loading control of membrane protein.
In vivo experiments
Five-week-oldmaleSCIDmice(CLEAJapan,Tokyo,Japan)were
injected intraperitoneally with 100 mg of rabbit anti-acialo-GM1
antibody (Wako, Osaka, Japan) for the inactivation of NK cells one
day before the subcutaneous inoculation of RPMI8226 cells (1610
6).
After confirmation that tumors over 100 mm
3 has formed, the mice
were intraperitoneally injected 3 times a week with 200 mlo fP B S ,
DOX (0.5 mg/kg), 3BrPA (5mg/kg), or DOX plus 3BrPA. Tumor
volume and body weight were measured before each injection.
Tumor volume was calculated as length 6width 6height/2.
Statistical analysis
Data are represented as means +/2 standard deviations unless
specified otherwise.Statisticalsignificancewasdetermined bya one-
way analysis of variance (ANOVA) with Scheffe’s post hoc tests or
Student’s t-test. The minimal level of significance was P=0.05.
Results
Inhibition of glycolysis by 3BrPA reduces ATP production
and induces cell death preferentially in malignant cells
Malignant cells have been demonstrated to produce a large
amount of ATP through glycolysis [10,11,12,14,15]. In order to
clarify the role of glycolysis in ATP production in malignant and
normal cells, we first measured the intracellular levels of ATP
upon treatment with the hexokinase II inhibitor 3BrPA, a potent
glycolysis inhibitor, in malignant cells. ATP levels in RPMI8226
multiple myeloma (MM) cells were substantially decreased by
3BrPA at 30 mM in as little as 30 minutes (Figure 1A). The effects
were dose-dependent and persisted at the same levels for 2 hours.
3BrPA similarly suppressed ATP production in KG-1 leukemic
cells (Figure 1A). Because the levels of lactate production reflect
glycolytic activity, we also measured the levels of lactate produced
by RPMI8226 and KG1 cells to determine glycolytic activity.
Addition of 3BrPA reduced the lactate production in these cells
(Figure 1B), confirming the inhibition of glycolysis by 3BrPA.
MM remains essentially incurable by conventional treatment,
and represents a drug-resistant hematological malignany [20,21].
MM cells reside in the bone marrow with normal hematopoietic
cells. To compare the effects of inhibiting glycolysis on ATP
production between malignant and normal cells, we isolated
CD138
+ primary MM cells and CD138
- non-MM cells from bone
marrow samples of patients with MM and PBMCs from normal
subjects. Treatment with 3BrPA at 50 mM suppressed ATP
production markedly in CD138
+ primary MM cells as in
RPMI8226 cells but only partially in normal CD138
- bone
marrow cells and PBMCs (Figure 1C–D). These results are
consistent with the notion that ATP production is dependent on
glycolysis in malignant cells. We next examined whether the
depletion of ATP causes tumor-specific impairment of cell
viability. 3BrPA dose-dependently reduced CD138
+ MM cell
fractions in bone marrow mononuclear cells from patients with
MM (Figure 1E). Of note, after treatment with 3BrPA at 90 mM,
the MM fractions were almost extinguished while remaining non-
MM bone marrow cells. 3BrPA at 30 mM also induced cell death
in RPMI8226 and INA6 MM and KG1 leukemic cells but
marginally in normal PBMCs (Figure 1F). These results suggest
that inhibition of glycolysis preferentially targets malignant cells to
suppress ATP production and induce cell death.
Inhibition of glycolysis by 3BrPA enhances drug
accumulation and retention in ABC transporter-
expressing malignant cells
To examine whether the ABC transporter activity in malignant
cells depends on ATP produced by enhanced glycolysis, we first
looked for ABC transporter-expressing malignant cells. After
screening, we obtained three malignant cell lines with high ABC
transporter expression: RPMI8226 MM and KG-1 leukemic cells
Figure 1. Reduction in ATP production and viability of malignant cells by 3BrPA. A. RPMI8226 and KG1 cells were cultured with 3BrPA at
10, 30 and 50 mM. Cellular levels of ATP were measured at different time points as indicated. B. RPMI8226 and KG1 cells were cultured for 2 hours in
the absence or presence of 3BrPA at 50 mM. The levels of lactate in their culture supernatants were measured. C, D. CD138
+ primary MM cells and
CD138
- non-MM BMMCs cells or PBMCs were cultured for 60 minutes with 50 mM of 3BrPA, and cellular levels of ATP were measured. Data were
expressed relative values for untreated cells. *, P,0.05 E. BMMCs from patients with MM were cultured for 3 days with 30 and 90 mM of 3BrPA. The
cells were then stained with PE-labeled anti-CD138 antibody, and analyzed by flow cytometry. Cell distributions were analyzed by the intensity of side
scatter (ss) vs. CD138 levels, and rectangles contained CD138
+ MM cells. F. RPMI8226, INA-6 and KG1 cells, and PBMCs were cultured for 24 hours
with 3BrPA at the indicated concentrations. The cells were stained with PI for and analyzed by flow cytometry.
doi:10.1371/journal.pone.0027222.g001
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tively (Figure 2A), while HepG2 hepatoma cells weakly expressed
BCRP and strongly expressed P-glycoprotein.
We next examined the effects of inhibition of glycolysis on ABC
transporter activity in these ABC transporter-expressing cells.
ABC transporter activity was determined based on the intracel-
lular accumulation and retention of daunorubicin and mitoxan-
trone, auto-fluorescence emitting anti-cancer agents known as a
substrate for ABC transporters [22,23]. KG1 cells pretreated with
3BrPA were further incubated with daunorubicin for 30 minutes
to passively incorporate it into the cells. 3BrPA dose-dependently
increased intracellular daunorubicin levels after the 30-minute
drug accumulation phase (Figure 2B). To analyze the intracellular
retention of the drug, the cells were washed and incubated for
2 hours in medium without daunorubicin. After the incubation,
the cellular content of daunorubicin was markedly reduced in the
absence of 3BrPA as observed by MIF levels from 43.78 to 16.55
(Figure 2B). However, most of the daunorubicin was retained in
KG-1 cells in the presence of 3BrPA at 30 and 50 mM,
concentrations high enough to reduce intracellular ATP levels as
shown in Fig. 1B. These results suggest that 3BrPA is able to
effectively accumulate and retain daunorubicin in ABC transport-
er-expressing malignant cells. The potential use of 3BrPA for
intracellular drug accumulation and retention was further studied
with ABC transporter-expressing RPMI8226 and HepG2 cells
(Figure 2C). 3BrPA at 50 mM enhanced the accumulation of
daunorubicin and restored its retention in these cells as observed in
KG-1 cells. Similar results were obtained with mitoxantrone in
KG-1 and RPMI8226 cells (Figure 2D). Because surface levels of
P-glycoprotein and BCRP were not changed in KG1 and
RPMI8226 cells, respectively, after the treatment with 3BrPA
(Figure S1), these results suggest that ABC transporter activity is
dependent on glycolysis in malignant cells, and that depletion of
intracellular ATP by inhibition of glycolysis is able to inactivate
ABC transporters to retain anti-cancer agents in malignant cells.
Inhibition of glycolysis by 3BrPA effectively suppresses
ATP production and drug efflux function in SP cells
Cell fractions with high ABC transporter activity are observed
as a SP by Hoechst33342 dye staining which has been recognized
in a variety of cancers [6,7,8,9]. SP fractions are considered to
contain cancer stem-like cells or cancer-initiating cells which are
capable of self-renewal and play a critical role in drug resistance
and relapse of tumors [1,2]. Because of the clonogenic and
proliferative capacity of SP cells, we assumed that glycolysis might
be further enhanced in SP fractions in malignant cells to supply
ATP and biomass to potentiate their growth and that inhibition of
glycolysis could be an effective way of targeting SP cells. Because
SP fractions were clearly observed in RPMI8226, DU145 prostate
cancer, and MDA-MB231 breast cancer cell lines, we sorted SP
and MP cells from these cells, and examined the status of glycolysis
in these fractions and the impact of glycolysis inhibition on ATP
production. We first looked at clonogenic capacity using colony
formation in a semi-solid medium. Colony formation was
enhanced about 6-fold in SP cells isolated from RPMI8226 cells
compared to in MP cells (Figure 3A), confirming the clonogenic
capacity of the SP cells. Surface levels of BCRP were also higher in
the SP cells than MP cells (Figure 3B). SP cells isolated from
RPMI8226 and MDA-MB231 cells exhibited an increased
expression of genes involved in the glycolytic pathway including
GLUT1, GLUT3, PDK1 and PFK2 (Figure S2). SP cells generated a
larger amount of ATP per cell compared to MP cells in
RPMI8226, DU145, and MDA-MB231 cells (Figure 3C). Lactate
production per cell was also markedly increased in SP cells from
RPMI8226 cells compared to that in MP cells (Figure 3D), which
further corroborate the enhancement of glycolysis in SP fractions.
These results suggest that glycolysis is highly accelerated in SP
cells. However, 3BrPA at 50 mM mostly suppressed the ATP
production in SP cells to levels similar to those in MP cells
(Figure 3C).
As demonstrated by Hoechst33342 dye staining, SP cells are
characterized as a cell population with enhanced ABC transporter
activity. Interestingly, SP cells were hardly detected in RPMI8226
and KG1 cells after treatment with 3BrPA as observed upon
treatment with verapamil, an inhibitor of ABC transporters
(Figure 3E). Similar results were obtained in DU145 and MDA-
MB231 non-hematopoietic cancer cell lines. From these observa-
tions, the inhibition of glycolysis is suggested to effectively
inactivate the ABC transporter function enhanced in SP cells.
Inhibition of glycolysis by 3BrPA abrogates the colony
forming capacity of malignant cells
Given that glycolysis is highly enhanced in cells with tumor-
initiating or progenitor potential in malignant tumors as observed
in SP cells, the inhibition of glycolysis may enable the targeting of
these cells to disrupt their clonogenic capacity. Therefore, we next
examined the effects of 3BrPA on the formation of colonies by
RPMI8226, KG1, HepG2, and DU145 cells. The ability of these
cells to form colonies was strikingly reduced by 3BrPA (Figure 4).
The results suggest that malignant cells with clonogenic capacity
appear to be susceptible to damage through the inhibition of
glycolysis.
Inhibition of glycolysis by 3BrPA enhances the
tumoricidal effects of anti-cancer agents on ABC
transporter-expressing malignant cells
Since the inhibition of glycolysis inactivates ABC transporters to
retain anti-cancer agents in malignant cells (Figure 2B–C), we next
examined the tumoricidal effects of anti-cancer agents in
combination with 3BrPA in ABC transporter-expressing malig-
nant cells. Exposure to daunorubicin dose-dependently induced
cell death in KG-1 cells (Figure 5A). Co-treatment with 3BrPA
substantially increased the cytotoxic effects of daunorubicin even
at low concentrations, 0.2 and 0.4 mM, although 3BrPA alone only
partially induced cell death in KG-1 cells. Similar results were
obtained on the treatment of RPMI8226 cells with doxorubicin
plus 3BrPA (Figure 5B). The effects of the combined treatment
were further studied in vivo using SCID mice implanted
subcutaneously with RPMI8226 cells. After confirmation that
subcutaneous tumors had formed, mice were treated with
doxorubicin, 3BrPA, or both. Doxorubicin or 3BrPA alone at
these dosages had only marginal effects on tumor growth
Figure 2. Inactivation of ABC transporter activity in malignant cells by 3BrPA. A. Surface expression of ABC transporters in KG1, RPMI8226
and HepG2 cells. B. KG1 cells were cultured with 3BrPA at the indicated concentrations. After 30 minutes, daunorubicin was added and the cultures
incubated for 30 minutes (accumulation phase, AP). The cells were then washed and further incubated for 2 hours in medium without daunorubicin
in the presence of 3BrPA at the indicated concentrations (efflux phase, EP). C, D. Fluorescein intensity was measured by flow cytometry to represent
intracellular levels of daunorubicin. The intracellular retention of daunorubicin in RPMI8226 and HepG2 cells and mitoxantrone in KG1 and RPMI8226
cells was similarly analyzed.
doi:10.1371/journal.pone.0027222.g002
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subcutaneous tumor growth, indicating cooperative tumoricidal
effects in vivo. The body weights of the mice did not change
significantly during the course of treatment in any group (Figure
S3). These results suggest that glycolysis inhibition restores the
susceptibility of ABC transporter-expressing cells to chemothera-
peutic agents.
Discussion
Cancer cells eventually acquire drug resistance often through
the aberrant expression of drug-expelling ABC transporters [2,4].
Overexpression of ABC transporters prevents the sufficient
accumulation of anticancer drugs within cells thereby confering
drug resistance [22,23]. Stem cell-like populations have been
identified in a variety of hematopoietic and solid tumors [7,8,9].
Besides their clonogenic or tumor-initiating capacity, they exhibit
high levels of ABC transporter expression and activity and confer
resistance to drugs. Given the existence of cancer stem cells with
ABC transporters, tumors can survive chemotherapy and
eventually regrow. Therefore, ABC transporters are widely
considered to be one of the most critical targets in the treatment
of cancers, especially those with drug resistance. Various selective
inhibitors of ABC transporters have been developed, and some are
under clinical testing [24,25,26]. Most of them appear to compete
with anti-cancer agents for the same binding site of certain ABC
transporters [26,27]. Other approaches include a molecular
genetic strategy to selectively block the expression of individual
ABC transporters using hammerhead ribozymes and antisense
oligonucleotides [24,25,26]. However, drug-resistant cancer cells
express multiple ABC transporters which act to expel drugs.
Therefore, the efficacy of the above strategies targeting a single
transporter appears to be limited. In contrast, inhibition of
glycolysis is able to simultaneously inactivate all types of ABC
transporters in cancer cells, because each transporter is dependent
on ATP generated largely through enhanced glycolysis.
The mechanisms critical to the enhancement of glycolysis in
cancer cells have been increasingly evident to be different from
Figure 4. Inhibition of colony formation in malignant cells by 3BrPA. Cells were cultured in the presence of 3BrPA at the indicated
concentrations in semi-solid metylcellulose medium. Colony numbers were counted after 2 weeks of culturing. Images of representative colonies
formed in semi-solid medium were shown in the lower panels (x100, original magnification).
doi:10.1371/journal.pone.0027222.g004
Figure 3. ATP production and drug efflux function in SP cells treated with 3BrPA. A. SP or MP cells were sorted from RPMI8226 cells, and
cultured in medium containing methylcellulose. After 14 days, colonies were counted. B. Surface expression of BCRP in SP and MP cells. C. Cellular
ATP levels in SP and MP cells. SP and MP cells from RPMI8226 cells were cultured for 60 minutes with 50 mM of 3BrPA, and then cellular ATP levels
were measured. Cellular ATP levels were measured in SP and MP cells from DU145 and MDA-MB231 cells. *, P,0.05 D. SP and MP cells from
RPMI8226 cells were cultured for 2 hours, and then lactate levels in their culture supernatants were measured. E. Substantial reduction of SP fractions
by 3BrPA. RPMI8226, KG1, DU145, and MDA-MB231 cells were stained with Hoechst 33342 for 90 min in the presence of 3BrPA at 50 mM. Verapamil
was added at 100 mM to determine SP cells, and distribution areas of SP cells were indicated.
doi:10.1371/journal.pone.0027222.g003
Glycolysis Inhibition Overcomes Drug Resistance
PLoS ONE | www.plosone.org 8 November 2011 | Volume 6 | Issue 11 | e27222those in normal cells [28]. Certain isoforms of enzymes such as
HKII [27,29,30] and PKM2 [31,32] have been reported to be
aberrantly up-regulated and responsible for the enhancement of
glycolysis exclusively in cancer cells. Consistently, 3BrPA, a HKII
inhibitor, preferentially acts on MM cells but marginally on
normal cells (Figure 1C–F). In addition, 3BrPA markedly
suppresses cell viability of clonogenic malignant cells (Figure 4)
and inactivates ABC transporters in malignant cells including SP
cells (Figure 2B–D, 3E). Although enhanced glycolysis is regarded
as a characteristic feature of cancer cells [10,12,14,15] and
particularly SP fractions (Figure 3C–D, Figure S2), some types of
normal cells increase glycolysis to maintain their metabolism in a
context-dependent manner [11,14]. In contrast to the constitutive
enhancement of glycolysis in cancer cells in normal oxygen
tension, hypoxia triggers to enhance glycolysis in normal cells.
Hematopoietic stem cells have been demonstrated to reside within
hypoxic areas in bone marrow and thus exhibit high glycolytic
activity and low oxidative phosphorylation in the bone marrow
[33,34]. Although the inhibition of glycolysis appears to affect
malignant cells but not normal quiescent mature hematopoietic
cells (Figure 1C–E), further study is needed to evaluate the overall
efficacy and toxicity of the inhibition of glycolysis in vivo.
The enhancement of glycolysis can also cause drug resistance in
malignant cells through mechanisms other than the activation of
ABC transporters. Acute lymphoblastic leukemia cells resistant to
glucocorticoids have been reported to show aberrant change in the
expression of glycolytic pathway-associated genes and increased
glucose consumption compared with sensitive cells, and inhibition
of glycolysis can resensitize the prednisolone-resistant leukemia
cells with high metabolic activity without affecting the efflux of
glucocorticoids [35]. Together with the present observations,
inhibition of glycolysis is suggested to be able to effectively target
drug-resistant and clonogenic tumor cells with a high metabolic
state, and impair their metabolism to restore cytotoxic effects of
anti-cancer agents. Therefore, these findings highlight a novel role
for enhanced glycolysis in malignant cells in tumor growth and
Figure 6. Suppression of tumor growth by 3BrPA and doxorubicin in vivo. RPMI8226 cells were subcutaneously inoculated into 5-week-old
male SCID mice. After the formation of subcutaneous tumors over 100 mm
3, the mice were treated 3 times a week for 3 weeks with either PBS,
doxorubicin (0.5 mg/kg), 3BrPA (5mg/kg) or doxorubicin plus 3BrPA (n=5 for each group). The results were expressed as fold increases in tumor
volume from the baseline. *, P,0.05s.
doi:10.1371/journal.pone.0027222.g006
Figure 5. Enhancement of cytotoxic effects of anti-cancer agents by 3BrPA on ABC transporter-expressing malignant cells. A, B. KG1
and RPMI8226 cells were treated with daunorubicin for 60 minutes and doxorubicin for 90 minutes at the indicated concentrations, respectively,
followed by 3BrPA. KG1 and RPMI8226 cells were then cultured with for a further 60 and 10 minutes, respectively, in the absence of 3BrPA or with
50 mM of 3BrPA. The cells were washed to remove 3BrPA and the drugs, and cultured for 22 hours in drug-free medium. Cell viability was determined
by WST-8 assays.
doi:10.1371/journal.pone.0027222.g005
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Supporting Information
Figure S1 Surface membrane ABC transporter levels by
glycolysis inhibition. A. RPMI8226 cells were cultured for
4 hours in the presence or absence of 3BrPA, and harvested.
Membrane protein level of was analyzed by immunoblotting. B.
Surface expression levels of P-glycoprotein in KG1 cells were
analyzed by flow cytometry after culturing for 1 hour in the
presence or absence of 3BrPA.
(TIF)
Figure S2 Glycolytic gene expression. Expression of genes
involved in the glycolytic pathway were analyzed in SP and MP
cells by quantitative real-time PCR.
(TIF)
Figure S3 Body weight change. Body weights of the
RPMI8226-bearing mice were measured at every treatment.
(TIF)
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